KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Neogenomics (NEO) over the last 17 years, with Q3 2025 value amounting to $2.8 million.

  • Neogenomics' Change in Accured Expenses fell 3048.38% to $2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.3 million, marking a year-over-year decrease of 12817.76%. This contributed to the annual value of $9.3 million for FY2024, which is 2870.2% down from last year.
  • Latest data reveals that Neogenomics reported Change in Accured Expenses of $2.8 million as of Q3 2025, which was down 3048.38% from $8.6 million recorded in Q2 2025.
  • Over the past 5 years, Neogenomics' Change in Accured Expenses peaked at $13.6 million during Q2 2024, and registered a low of -$23.0 million during Q1 2025.
  • Over the past 5 years, Neogenomics' median Change in Accured Expenses value was $2.8 million (recorded in 2025), while the average stood at $1.3 million.
  • The largest annual percentage gain for Neogenomics' Change in Accured Expenses in the last 5 years was 48005.43% (2021), contrasted with its biggest fall of 64895.05% (2021).
  • Over the past 5 years, Neogenomics' Change in Accured Expenses (Quarter) stood at -$3.7 million in 2021, then soared by 158.12% to $2.2 million in 2022, then surged by 158.93% to $5.6 million in 2023, then surged by 84.64% to $10.3 million in 2024, then plummeted by 73.02% to $2.8 million in 2025.
  • Its Change in Accured Expenses stands at $2.8 million for Q3 2025, versus $8.6 million for Q2 2025 and -$23.0 million for Q1 2025.